Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 20/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 11/20 | 1.00 |
| ▸ | ADORA2A | P29274 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14517874 | 0.90 | ADORA2B (0.82) | ADORA2BADORA1ADORA2A | |
| SCHEMBL1779353 | 0.89 | ADORA2B (0.80) | ADORA2BADORA1ADORA2A | |
| SCHEMBL1780170 | 0.87 | ADORA2B (1.00) | ADORA2BADORA1ADORA2A | |
| SCHEMBL29742673 | 0.87 | ADORA2B (1.00) | ADORA2BADORA1ADORA2A | |
| SCHEMBL1780530 | 0.87 | ADORA2B (1.00) | ADORA2BADORA1ADORA2A | |
| SCHEMBL1780185 | 0.87 | ADORA2B (1.00) | ADORA2BADORA1ADORA2A | |
| SCHEMBL5331775 | 0.86 | ADORA2B (1.00) | ADORA2BADORA1ADORA2A | |
| SCHEMBL29352331 | 0.86 | ADORA2B (1.00) | ADORA2BADORA1ADORA2A | |
| SCHEMBL14267728 | 0.86 | ADORA2B (1.00) | ADORA2BADORA1ADORA2A | |
| SCHEMBL14267696 | 0.86 | ADORA2B (1.00) | ADORA2BADORA1ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240219394-A1 | METHOD FOR MEASURING RESPONSE OF OLFACTORY RECEPTOR TO SUBSTANCE | AJINOMOTO CO., INC. (JP) | 2024-07-04 | — | — | US | claimed |
| EP-4382612-A1 | METHOD FOR MEASURING RESPONSE OF OLFACTORY RECEPTOR TO SUBSTANCE | AJINOMOTO CO., INC. (JP) | 2024-06-12 | — | — | EP | claimed |
| CN-117321080-A | Combination therapy using anti-CD 38 antibodies and PARP or adenosine receptor inhibitors | 詹森生物科技公司 | 2023-12-29 | — | — | CN | claimed |
| EP-4294844-A1 | COMBINATION THERAPIES WITH ANTI-CD38 ANTIBODIES AND PARP OR ADENOSINE RECEPTOR INHIBITORS | Janssen Biotech, Inc. (US) | 2023-12-27 | — | — | EP | claimed |
| WO-2023013791-A1 | METHOD FOR MEASURING RESPONSE OF OLFACTORY RECEPTOR TO SUBSTANCE | 味の素株式会社 | 2023-02-09 | — | — | WO | claimed |
| US-20220275090-A1 | Combination Therapies with Anti-CD38 Antibodies and PARP or Adenosine Receptor Inhibitors | JANSSEN BIOTECH, INC. | 2022-09-01 | — | — | US | claimed |
| WO-2022175920-A1 | COMBINATION THERAPIES WITH ANTI-CD38 ANTIBODIES AND PARP OR ADENOSINE RECEPTOR INHIBITORS | JANSSEN BIOTECH, INC. (US) | 2022-08-25 | — | — | WO | claimed |
| WO-2014153424-A1 | REDUCING DIABETES IN PATIENTS RECEIVING HMG-COA REDUCTASE INHIBITORS (STATINS) | LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY (US) | 2014-09-25 | — | — | WO | claimed |
| US-20240219394-A1 | METHOD FOR MEASURING RESPONSE OF OLFACTORY RECEPTOR TO SUBSTANCE | AJINOMOTO CO., INC. (JP) | 2024-07-04 | — | — | US | disclosed |
| US-11857600-B2 | GPCR heteromer inhibitors and uses thereof | GPCR THERAPEUTICS, INC. (KR) | 2024-01-02 | — | — | US | disclosed |
| CN-117321080-A | Combination therapy using anti-CD 38 antibodies and PARP or adenosine receptor inhibitors | 詹森生物科技公司 | 2023-12-29 | — | — | CN | disclosed |
| EP-4294844-A1 | COMBINATION THERAPIES WITH ANTI-CD38 ANTIBODIES AND PARP OR ADENOSINE RECEPTOR INHIBITORS | Janssen Biotech, Inc. (US) | 2023-12-27 | — | — | EP | disclosed |
| US-20230181469-A1 | MICROPARTICLE FORMULATIONS OF ADENOSINE RECEPTOR ANTAGONISTS FOR TREATING CANCER | CYTODIGM, INC. | 2023-06-15 | — | — | US | disclosed |
| WO-2023013791-A1 | METHOD FOR MEASURING RESPONSE OF OLFACTORY RECEPTOR TO SUBSTANCE | 味の素株式会社 | 2023-02-09 | — | — | WO | disclosed |
| WO-2008131922-A1 | NEW 4,8-DIPHENYL-POLYAZANAPHTHALENE DERIVATIVES | ALMIRALL, S.A. (ES) | 2008-11-06 | — | — | WO | disclosed |
| WO-2008107125-A1 | NEW 3-([1,2,4]TRIAZOLO[4,3-A]PYRIDIN-7-YL)BENZAMIDE DERIVATIVES | ALMIRALL, S.A. (ES) | 2008-09-12 | — | — | WO | disclosed |
| US-7335655-B2 | 8-heteroaryl xanthine adenosine A2B receptor antagonists | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) | 2008-02-26 | — | — | US | disclosed |
| US-7335655-B2 | 8-heteroaryl xanthine adenosine A2B receptor antagonists | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) | 2008-02-26 | — | — | US | disclosed |
| US-7205403-B2 | 8-Heteroaryl xanthine adenosine A2B receptor antagonists | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) | 2007-04-17 | — | — | US | disclosed |
| US-7205403-B2 | 8-Heteroaryl xanthine adenosine A2B receptor antagonists | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) | 2007-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220275090-A1 | Combination Therapies with Anti-CD38 Antibodies and PARP or Adenosine Receptor Inhibitors | CD38, PARP1, PARP11 | ADORA2B 38/4885ADORA1 25/4885ADORA2A 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.